Multiple myeloma: open trials in Denmark

27 open trials have a site in Denmark. Registry data; only the trial team decides who can take part.

NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Aalborg University Hospital, Aalborg · Region Midtjylland, Herning · Næstved Hospital, Næstved · Sygehus Lillebaelt - Vejle Sygehus, Vejle
Registry updated 2026-11-03
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C · Region Sjaelland, Roskilde
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Aarhus Universitetshospital, Aarhus N · Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C · Lillebaelt Hospital, Vejle
Registry updated 2026-10-27
NCT07634263
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
Research · Odense University Hospital
Copenhagen University Hospital, Rigshospitalet, Copenhagen · Odense University Hospital, Odense · Sjællands Universitets Hospital, Roskilde
Registry updated 2026-10-23
NCT07735637
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Trial Treatment · Phase 3 · AstraZeneca
Aarhus · København Ø · Odense
Registry updated 2026-10-21
NCT04910568
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · Genentech, Inc.
Rigshospitalet, Copenhagen Oe
Registry updated 2026-10-20
NCT07878208
Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies
Research · Odense University Hospital
Aarhus University Hospital, Aarhus · Copenhagen University Hospital, Copenhagen · Regional Hospital Gødstrup, Gødstrup · Odense University Hospital, Odense · Zealand University Hospital, Roskilde, Roskilde · Vejle Hospital, Vejle
Registry updated 2026-10-16
NCT07648264
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Trial Treatment · Phase 3 · CSL Behring
Rigshospitalet, Copenhagen · Zealand University Hospital, Roskilde · Department of Medicine, Vejle Hospital, Vejle
Registry updated 2026-10-14
NCT06980480
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Trial Treatment · Phase 3 · Takeda
Aalborg University Hospital, Aalborg · Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C
Registry updated 2026-10-13
NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Trial Treatment · Phase 3 · Hoffmann-La Roche
Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe · Region Sjaelland, Roskilde · Lillebaelt Hospital, Vejle
Registry updated 2026-10-13
2026-525367-40-00
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
Trial Treatment · Phase 3 · AstraZeneca AB
Region Midtjylland, Aarhus N · Region Hovedstaden, Copenhagen Oe · Region Syddanmark, Odense C
Registry updated 2026-10-12
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Aarhus Universitetshospital, Aarhus N · Rigshospitalet, Copenhagen Oe · Odense University Hospital, Nyborg · Lillebaelt Hospital, Vejle
Registry updated 2026-10-07
NCT07842198
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
Trial Treatment · Phase 2 · Zealand University Hospital
Zealand University Hospital, Roskilde
Registry updated 2026-09-25
2025-524014-29-00
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
Trial Treatment · Phase 3 · AstraZeneca AB
Region Midtjylland, Aarhus N
Registry updated 2026-09-08
NCT06285318
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Research · Janssen-Cilag Ltd.
Aalborg Sygehus Syd, Aalborg · Aarhus Universitetshospital, Aarhus N · Rigshospitalet, Copenhagen · Odense University Hospital, Odense · Sygehus Lillebælt - Vejle, Vejle
Registry updated 2026-08-28
NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Trial Treatment · Phase 3 · Pfizer
Aalborg University Hospital, Aalborg · Aarhus Universitetshospital, Aarhus N · Rigshospitalet, Copenhagen Oe
Registry updated 2026-08-24
NCT07764978
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Trial Treatment · Phase 3 · AstraZeneca
Århus N
Registry updated 2026-08-14
NCT05444348
Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)
Trial Treatment · Christoffer Johansen
Aalborg Universitetshospital, Aalborg · Aarhus Universitetshospital, Aarhus · Sydvestjysk sygehus - Esbjerg, Esbjerg · Regionshospitalet Gødstrup, Herning · Odense Universitetshospital, Odense · Sjællands Universitetshospital_Roskilde, Roskilde · Lillebælt syge - Vejle Sygehus, Vejle
Registry updated 2026-08-12
NCT07757412
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
Trial Treatment · Phase 2 · Odense University Hospital
Region Midtjylland, Aarhus N · Odense University Hospital, Odense C
Registry updated 2026-08-11
NCT04077307
A Study in Leukemia Patients With Karonudib
Trial Treatment · Phase 1 · Thomas Helleday Foundation
Aarhus University Hospital, Aarhus · Rigshospitalet (Copenhagen University Hospital), Copenhagen
Registry updated 2026-08-06
NCT05650632
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · AbbVie
Odense University Hospital, Odense C · Lillebaelt Hospital, Vejle
Registry updated 2026-07-13
NCT07558057
Cognitive Impairment in Patients Undergoing Cell- and Antibody-based Immunotherapies for Haematological Malignancies: The COGNITOX Study
Research · Aarhus University Hospital
Aarhus University Hospital, Aarhus
Registry updated 2026-04-30
NCT06932562
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Region Midtjylland, Aarhus N · Region Sjaelland, Roskilde
Registry updated 2026-03-25
NCT07474961
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
Trial Treatment · Phase 4 · Anne Louise Tølbøll Sørensen
Aalborg University Hospital, Aalborg · Aarhus University Hospital, Aarhus · Copenhagen University Hospital, Rigshospitalet, Copenhagen · Odense University Hospital, Odense · Roskilde University Hospital, Roskilde
Registry updated 2026-03-16
NCT06015542
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Trial Treatment · Phase 2 · Thomas Lund
Odense University Hospital, Odense C · Sygehus Lillebaelt - Vejle Sygehus, Vejle
Registry updated 2026-02-10

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error